Turning Point Therapeutics Inc. (TPTX) PT Raised to $84 at Wedbush
- Stocks down for third day, yields jump as markets prep for rate hikes
- Ford (F) Stock Soars on $11.4 Billion EV Partnership with Battery Maker SK Innovation (SKOVF)
- Brent tops $80 a barrel on tighter supplies
- Merck (MRK) Said to Be Unidentified Suitor for Acceleron Pharma (XLRN), Not Bristol-Myers Squibb (BMY) - Report
- Scientific Games (SGMS), Endeavor Group (EDR) Both Gain on $1.2B OpenBet Deal
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Wedbush analyst David Nierengarten raised the price target on Turning Point Therapeutics Inc. (NASDAQ: TPTX) to $84.00 (from $63.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: SeaSpine Holdings (SPNE) PT Lowered to $30.25 at Ladenburg Thalmann, 'CE Mark Expands Commercial Opportunity to Europe'
- Recruit Holdings Co., Ltd (6098:JP) (RCRUY) PT Raised to JPY8,000 at Morgan Stanley
- Teledyne (TDY) PT Raised to $570 at Berenberg
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!